Hangzhou Yingbairui Biomedical Technology

InnoPinnacle is a clinical-stage biotechnology company based in Hangzhou, China, specializing in the development of innovative cell therapies and antibody-based drugs. The company focuses on the research and industrialization of Chimeric Antigen Receptor Natural Killer (CAR-NK) cell therapies and bispecific antibodies for the treatment of solid tumors and hematological malignancies. InnoPinnacle leverages its proprietary technology platforms to overcome the limitations of traditional CAR-T therapies, such as safety concerns and high costs, by utilizing off-the-shelf NK cell products. Their lead programs target high-value oncology markers including Claudin 18.2 and Mesothelin, with several candidates currently in clinical trials.